Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic
astrocytoma (AA), comprise the majority of all primary brain tumors in adults. This group of
tumors also exhibits the most aggressive behavior, resulting in median overall survival
durations of only 9-12 months for GBM, and 3-4 years for AA. Initial therapy consists of
either surgical resection, external beam radiation or both. All patients experience a
recurrence after first-line therapy, so improvements in both first-line and salvage therapy
are critical to enhancing quality-of-life and prolonging survival. It is unknown if currently
used intravenous (IV) therapies even cross the blood brain barrier (BBB). The investigators
have shown in a previous phase I trial that a single Super-selective Intraarterial Cerebral
Infusion (SIACI) of Bevacizumab (up to 15mg/kg) is safe and effective in the treatment of
recurrent GBM. Therefore, this phase I/II clinical research trial is an extension of that
trial in that the investigators seek to test the hypothesis that repeated dosing of
intraarterial Bevacizumab is safe and effective in the treatment of recurrent malignant
glioma. By achieving the aims of this study the investigators will also determine if IV
therapy with Bevacizumab should be combined with repeated selected intraarterial Bevacizumab
to improve progression free and overall survival. The investigators expect that this project
will provide important information regarding the utility of repeated SIACI Bevacizumab
therapy for malignant glioma, and may alter the way these drugs are delivered to the patients
in the near future.